SKK
RCKT icon

Shepherd Kaplan Krochuk’s Rocket Pharmaceuticals RCKT Stock Holding History

Shepherd Kaplan Krochuk’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q3 		– Sell
-5,125
Closed -$39K – 237
2017
Q2 		$39K Sell
5,125
-3,875
-43% -$28.9K 0.02% 232
2017
Q1 		$72K Buy
9,000
+2,731
+44% +$18.4K 0.04% 227
2016
Q4 		$153K Sell
6,269
-8,067
-56% -$230K 0.04% 194
2016
Q3 		$544K Hold
14,336
– – 0.11% 121
2016
Q2 		$427K Buy
+14,336
New +$504K 0.11% 131

Other funds holding RCKT

OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Jennison Associates
Jennison Associates New York $167B AUM 44.17% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
PVI
Pura Vida Investments New York $37M AUM 63.54% 1-Year Est. Return
SAM
Senzar Asset Management New York $34.7M AUM 0.56% 1-Year Est. Return
Point72 Asset Management
Point72 Asset Management Stamford, Connecticut $90.7B AUM 77.13% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $767M AUM 119.71% 1-Year Est. Return
GCP
GSA Capital Partners London, United Kingdom $1.59B AUM 39.81% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Shepherd Kaplan Krochuk's RCKT Position: Q3 2017 in Review

Shepherd Kaplan Krochuk sold out of Rocket Pharmaceuticals (RCKT) in Q3 2017, closing a stake of 5,125 shares — an estimated $39K sold.

Shepherd Kaplan Krochuk first reported a position in RCKT in Q2 2016 and held it in 5 quarters. The position peaked at $544K in Q3 2016. 35 funds tracked by Wall St. Rank hold RCKT as of Q3 2017.

  • Shepherd Kaplan Krochuk reported no remaining Rocket Pharmaceuticals position as of Q3 2017 after selling out during the quarter.
  • Shepherd Kaplan Krochuk sold 5,125 Rocket Pharmaceuticals shares in Q3 2017, an estimated $39K.
  • Shepherd Kaplan Krochuk first reported a position in Rocket Pharmaceuticals in Q2 2016 and held it in 5 quarters.
  • Shepherd Kaplan Krochuk's Rocket Pharmaceuticals position peaked at $544K in Q3 2016.
  • 35 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q3 2017.

Based on Shepherd Kaplan Krochuk's 13F filing for Q3 2017, filed 14 Nov 2017.